List of works by Robert Schlossman

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

scientific article published in September 2002

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

scientific article published on 08 May 2018

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

scientific article

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

scientific article

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

scientific article published in August 2002

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

scientific article

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy

scientific article published on 23 June 2014

Bortezomib in the front-line treatment of multiple myeloma

scientific article published on July 2008

Bortezomib in the management of multiple myeloma.

scientific article

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

scientific article published in April 2008

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

scientific article

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

scientific article published in February 2010

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

scientific article

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

scientific article published on June 2015

Emerging drugs in multiple myeloma

scientific article published on March 2007

Emerging trends in the clinical use of bortezomib in multiple myeloma

scientific article

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study

scientific article

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function

scientific article published on 03 August 2004

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

scientific article published on 26 November 2003

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

scientific article published on July 2005

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

scientific article published on February 2002

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

scientific article

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

scientific article published on December 2005

Lenalidomide after stem-cell transplantation for multiple myeloma

scientific article

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

scientific article published on 27 November 2017

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

scientific article published on June 15, 2010

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

scientific article

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

scientific article

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.

scientific article published on June 2011

Management of myeloma-associated renal dysfunction in the era of novel therapies

scientific article published on February 2012

Management of relapsed and relapsed/refractory multiple myeloma

scientific article published on 01 October 2011

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings

scientific article published on 07 July 2011

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

scientific article

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

scientific article published on 26 September 2002

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

scientific article published on 16 January 2003

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

scientific article

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

scientific article

New drugs for myeloma

scientific article published on June 2007

New treatments for multiple myeloma.

scientific article

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

scientific article published on June 2007

Novel therapies in the treatment of multiple myeloma

scientific article published on October 2009

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

scientific article published in October 2007

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

scientific article

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

scientific article published on 14 October 2016

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

scientific article

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

scientific article

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

scientific article

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

scientific article published on 11 October 2011

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

scientific article

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

scientific article published on July 2006

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

scientific article published on 15 June 2009

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

scientific article published in March 2010

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

scientific article

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

scientific article published on 5 September 2002

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

scientific article published in July 2004

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma

scientific article published on February 2011

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms

scientific article published on 22 November 2011

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

scientific article published on 11 December 2003

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

scientific article published on 07 March 2012

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

scientific article published on 7 November 2002

The treatment of multiple myeloma patients not eligible for asct

scientific article

The treatment of relapsed and refractory multiple myeloma

scientific article published on January 2007

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

scientific article

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

scientific article published on 14 March 2010

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

scientific article

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma

scientific article published in June 2003

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

scientific article

Paulina is supported by:

About Paulina

Help